AUG 12, 2021
UHC Leads in Patient Safety, Drops Biosimilars As Ophthalmic Avastin Alternatives
United Healthcare (UHC), one of the insurers that had listed two untested biosimilars in its policies as alternatives to intravitreal Avastin, said Tuesday that Mvasi and Zirabev have been removed from its maximum dosage (PDF) and anti-VEGF commercial policies.
The clarifications UHC has made pertain only to the ophthalmic use of Zirabev and Mvasi.
Several insurers have been listing the biosimilars as Avastin alternatives for ophthalmic use since a supply chain disruption in the spring limited Avastin’s availability. The Academy is disappointed that other insurers have yet to announce any change in their policies. The Academy and ASRS will meet with CMS soon to discuss our shared concerns, particularly as Zirabev could be harmful to corneal tissue.
The Academy met with UHC two weeks ago to discuss our concern that the drugs are inappropriate alternatives for patients who need intravitreal anti-VEGF treatment. We appreciate the insurer’s willingness to listen to our position and to take the appropriate action to protect patients.
If you have further questions, contact healthpolicy@aao.org.